These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38367430)

  • 1. The first-in-class pyrazole-based dual InhA-VEGFR inhibitors towards integrated antitubercular host-directed therapy.
    Shaaban MM; Teleb M; Ragab HM; Singh M; Elwakil BH; A Heikal L; Sriram D; Mahran MA
    Bioorg Chem; 2024 Apr; 145():107179. PubMed ID: 38367430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, in vitro and in silico evaluation of novel substituted 1,2,4-triazole analogues as dual human VEGFR-2 and TB-InhA inhibitors.
    Zawal AG; Abdel-Aziz MM; Elbatreek MH; El-Shanawani AA; Abdel-Aziz LM; Elbaramawi SS
    Bioorg Chem; 2023 Dec; 141():106883. PubMed ID: 37774433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel diaryl ether derivatives as InhA inhibitors: Design, synthesis and antimycobacterial activity.
    Abdelaziz OA; Othman DIA; Abdel-Aziz MM; Badr SMI; Eisa HM
    Bioorg Chem; 2022 Dec; 129():106125. PubMed ID: 36126606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
    Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
    Lokesh BVS; Prasad YR; Shaik AB
    Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
    Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
    Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis.
    Freundlich JS; Wang F; Vilchèze C; Gulten G; Langley R; Schiehser GA; Jacobus DP; Jacobs WR; Sacchettini JC
    ChemMedChem; 2009 Feb; 4(2):241-8. PubMed ID: 19130456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
    Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
    J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation.
    Reda Aouad M; Almehmadi MA; Faleh Albelwi F; Teleb M; Tageldin GN; Abu-Serie MM; Hagar M; Rezki N
    Bioorg Chem; 2022 Jul; 124():105816. PubMed ID: 35489270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking.
    El Sawy MA; Elshatanofy MM; El Kilany Y; Kandeel K; Elwakil BH; Hagar M; Aouad MR; Albelwi FF; Rezki N; Jaremko M; El Ashry ESH
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
    Lu XY; You QD; Chen YD
    Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel N-methyl carbazole tethered rhodanine derivatives as direct inhibitors of Mycobacterium tuberculosis InhA.
    Shaikh MS; Kanhed AM; Chandrasekaran B; Palkar MB; Agrawal N; Lherbet C; Hampannavar GA; Karpoormath R
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2338-2344. PubMed ID: 31227345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do new N-substituted 3-amino-4-phenyl-5-oxo-pyrazolinecarboxamide derivatives exhibit antitubercular potential?
    Swatko-Ossor M; Klimek K; Belcarz A; Kaczor AA; Pitucha M; Ginalska G
    Eur J Pharm Sci; 2018 Aug; 121():155-165. PubMed ID: 29802898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, evaluation, molecular docking, and molecular dynamics studies of novel N-(4-[pyridin-2-yloxy]benzyl)arylamine derivatives as potential antitubercular agents.
    Verma R; Boshoff HIM; Arora K; Bairy I; Tiwari M; Varadaraj BG; Shenoy GG
    Drug Dev Res; 2020 May; 81(3):315-328. PubMed ID: 31782209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triclosan and its derivatives as antimycobacterial active agents.
    Vosátka R; Krátký M; Vinšová J
    Eur J Pharm Sci; 2018 Mar; 114():318-331. PubMed ID: 29277667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA).
    Khaleel EF; Sabt A; Korycka-Machala M; Badi RM; Son NT; Ha NX; Hamissa MF; Elsawi AE; Elkaeed EB; Dziadek B; Eldehna WM; Dziadek J
    Bioorg Chem; 2024 Mar; 144():107138. PubMed ID: 38262087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity.
    Nayak N; Ramprasad J; Dalimba U
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5540-5. PubMed ID: 26520663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays.
    Zhang Q; Han J; Zhu Y; Yu F; Hu X; Tong HHY; Liu H
    J Comput Aided Mol Des; 2023 Dec; 37(12):695-706. PubMed ID: 37642861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.